Compare Stocks → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADVMNASDAQ:ATRANASDAQ:OYSTNASDAQ:PRTONASDAQ:RCEL Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADVMAdverum Biotechnologies$10.19-7.4%$15.83$7.10▼$29.70$211.49M0.84241,171 shs313,647 shsATRAAtara Biotherapeutics$0.71$0.72$0.20▼$3.02$85.31M0.692.70 million shs697,941 shsOYSTOyster Point Pharma$11.17$11.15$3.46▼$19.00$299.85M1.31212,171 shs330 shsPRTOProteon Therapeutics$2.82-6.0%$19.37$0.22▼$3.94$62.55M0.61.11 million shs422,081 shsRCELAVITA Medical$8.57-4.6%$15.08$8.46▼$21.70$220.34M1.33211,645 shs149,342 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADVMAdverum Biotechnologies-7.36%-10.22%-31.84%+13.85%+23.95%ATRAAtara Biotherapeutics-0.54%-0.03%+6.69%+18.50%-75.01%OYSTOyster Point Pharma0.00%0.00%0.00%0.00%0.00%PRTOProteon Therapeutics-6.00%+3.30%-29.32%+43.15%-9.62%RCELAVITA Medical-4.57%-8.64%-45.98%-48.74%-38.08%top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADVMAdverum Biotechnologies4.0478 of 5 stars3.52.00.04.83.12.50.0ATRAAtara Biotherapeutics3.9823 of 5 stars3.02.00.04.73.12.50.6OYSTOyster Point PharmaN/AN/AN/AN/AN/AN/AN/AN/APRTOProteon TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ARCELAVITA Medical0.9301 of 5 stars3.42.00.00.01.10.00.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADVMAdverum Biotechnologies3.00Buy$34.67240.20% UpsideATRAAtara Biotherapeutics2.00Hold$28.003,817.73% UpsideOYSTOyster Point PharmaN/AN/AN/AN/APRTOProteon TherapeuticsN/AN/AN/AN/ARCELAVITA Medical2.80Moderate Buy$27.80224.39% UpsideCurrent Analyst RatingsLatest ATRA, ADVM, OYST, RCEL, and PRTO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/11/2024RCELAVITA MedicalBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral3/19/2024ADVMAdverum BiotechnologiesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.002/23/2024RCELAVITA MedicalPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$19.00 ➝ $21.002/23/2024RCELAVITA MedicalCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$22.00 ➝ $25.002/6/2024ADVMAdverum BiotechnologiesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $40.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADVMAdverum Biotechnologies$3.60M58.75N/AN/A$8.26 per share1.23ATRAAtara Biotherapeutics$8.57M9.95N/AN/A($0.97) per share-0.74OYSTOyster Point Pharma$24.54M12.22N/AN/A$3.80 per share2.94PRTOProteon TherapeuticsN/AN/AN/AN/A($0.06) per shareN/ARCELAVITA Medical$50.14M4.39N/AN/A$1.92 per share4.46Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADVMAdverum Biotechnologies-$117.17M-$11.60N/AN/AN/AN/A-98.65%-52.85%5/9/2024 (Estimated)ATRAAtara Biotherapeutics-$276.13M-$2.62N/AN/AN/A-3,220.88%-783.31%-122.34%5/13/2024 (Estimated)OYSTOyster Point Pharma-$100.66M-$6.65N/AN/AN/A-901.99%-490.33%-108.29%N/APRTOProteon Therapeutics-$20.73M-$1.15N/AN/AN/AN/AN/A-118.68%N/ARCELAVITA Medical-$35.38M-$1.40N/AN/AN/A-70.56%-54.80%-38.08%5/13/2024 (Confirmed)Latest ATRA, ADVM, OYST, RCEL, and PRTO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2024N/ARCELAVITA Medical-$0.26N/A+$0.26N/AN/AN/A 3/28/2024Q4 2023ATRAAtara Biotherapeutics-$0.61-$0.56+$0.05-$0.56$2.45 million$4.25 million3/18/2024Q4 2023ADVMAdverum Biotechnologies-$2.80-$2.30+$0.50-$2.30N/AN/A2/22/2024Q4 2023RCELAVITA Medical-$0.34-$0.28+$0.06-$0.28$14.10 million$14.20 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADVMAdverum BiotechnologiesN/AN/AN/AN/AN/AATRAAtara BiotherapeuticsN/AN/AN/AN/AN/AOYSTOyster Point PharmaN/AN/AN/AN/AN/APRTOProteon TherapeuticsN/AN/AN/AN/AN/ARCELAVITA MedicalN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADVMAdverum BiotechnologiesN/A4.134.13ATRAAtara BiotherapeuticsN/A0.720.65OYSTOyster Point Pharma8.493.353.11PRTOProteon TherapeuticsN/A5.985.98RCELAVITA Medical0.817.887.46OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADVMAdverum Biotechnologies48.17%ATRAAtara Biotherapeutics70.90%OYSTOyster Point Pharma96.70%PRTOProteon Therapeutics23.03%RCELAVITA Medical27.66%Insider OwnershipCompanyInsider OwnershipADVMAdverum Biotechnologies5.30%ATRAAtara Biotherapeutics4.50%OYSTOyster Point Pharma17.90%PRTOProteon Therapeutics45.70%RCELAVITA Medical2.05%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADVMAdverum Biotechnologies12120.76 million19.66 millionOptionableATRAAtara Biotherapeutics334119.36 million113.99 millionOptionableOYSTOyster Point Pharma30326.84 million22.04 millionNot OptionablePRTOProteon Therapeutics1722.18 millionN/ANot OptionableRCELAVITA Medical20725.71 million25.18 millionOptionableATRA, ADVM, OYST, RCEL, and PRTO HeadlinesSourceHeadlineAVITA Medical Inc RCELmorningstar.com - April 19 at 10:46 AMAVITA Medical to Announce First Quarter 2024 Financial Resultsglobenewswire.com - April 15 at 5:05 PMShort Interest in AVITA Medical, Inc. (NASDAQ:RCEL) Grows By 22.9%marketbeat.com - April 15 at 1:33 PMAvita Medical Ltd (RCEL)investing.com - April 11 at 11:20 PMAnalysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE), Disc Medicine (IRON) and Avita Medical (RCEL)markets.businessinsider.com - April 11 at 1:19 PMBTIG downgrades Avita to neutral, cites lowered guidanceseekingalpha.com - April 11 at 1:19 PMAVITA Medical (NASDAQ:RCEL) Rating Lowered to Neutral at BTIG Researchmarketbeat.com - April 11 at 8:11 AMAVITA Medical Updates Expected First Quarter 2024 Revenueglobenewswire.com - April 10 at 5:11 PMRCEL Apr 2024 22.500 putfinance.yahoo.com - March 16 at 8:16 AMRCEL Oct 2024 17.500 putfinance.yahoo.com - March 16 at 8:16 AMAVITA Medical: Unconvincing Growth Amid Fierce Competition In The Burn Care Sectorseekingalpha.com - March 5 at 2:05 PMAVITA Medical Submits Response to FDA, Resuming Review Clock for RECELL GO PMA Supplementfinance.yahoo.com - February 29 at 4:15 PMAVITA Medical Submits Response to FDA, Resuming Review Clock for RECELL GO PMA Supplementglobenewswire.com - February 29 at 4:02 PMAVITA Medical to Present at TD Cowen 44th Annual Health Care Conferenceglobenewswire.com - February 29 at 9:00 AMAVITA Medical (RCEL) Price Target Increased by 6.80% to 26.69nasdaq.com - February 26 at 10:49 PMBRIEF-Seatrium Limited Says FY Revenue S$7.3 Blnsg.finance.yahoo.com - February 26 at 1:49 AMAvita Medical Poised for Growth: Strong Q4 Performance and Promising 2024 Outlook Reinforce Buy Ratingmarkets.businessinsider.com - February 23 at 5:44 PMAVITA Medical, Inc. (NASDAQ:RCEL) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - February 23 at 12:43 PMAVITA Medical to Host Investor Webinar Briefingglobenewswire.com - February 23 at 9:01 AMArdelyx Posts Q4 Loss, Joins MercadoLibre, Booking Holdings And Other Big Stocks Moving Lower In Friday's Pre-Market Sessionmsn.com - February 23 at 7:35 AMBuy Rating Affirmed for Avita Medical on Strong Financials and Expansive Growth Strategymarkets.businessinsider.com - February 23 at 2:34 AMAVITA Medical Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidanceglobenewswire.com - February 22 at 4:01 PMAVITA Medical Q4 2023 Earnings Previewmsn.com - February 21 at 2:21 PMRCEL Mar 2024 15.000 callfinance.yahoo.com - February 17 at 12:44 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent3 Companies Buying Back Stock Before New HighsApril 1, 2024 6:05 AMView 3 Companies Buying Back Stock Before New HighsUnited Parcel Service Is Setting Up for Another FallApril 24, 2024 6:15 AMView United Parcel Service Is Setting Up for Another FallAmazon Stock Insights & Analysis for 2024 April 22, 2024 7:13 AMView Amazon Stock Insights & Analysis for 2024 All Headlines Company DescriptionsAdverum BiotechnologiesNASDAQ:ADVMAdverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.Atara BiotherapeuticsNASDAQ:ATRAAtara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.Oyster Point PharmaNASDAQ:OYSTOyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.Proteon TherapeuticsNASDAQ:PRTOProteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to enhance hemodialysis vascular access outcomes. The company develops vonapanitase, a recombinant human elastase, which has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. It is also evaluating vonapanitase in a Phase I clinical trial in patients with peripheral artery disease. The company was founded in 2001 and is based in Waltham, Massachusetts.AVITA MedicalNASDAQ:RCELAVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.